These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 30074151)

  • 21. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
    Hassanein M; Atenafu EG; Schuh AC; Yee KW; Minden MD; Schimmer AD; Gupta V; Brandwein JM
    Leuk Res; 2013 May; 37(5):556-60. PubMed ID: 23357460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
    Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
    J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
    Sanz MA; Lo Coco F; Martín G; Avvisati G; Rayón C; Barbui T; Díaz-Mediavilla J; Fioritoni G; González JD; Liso V; Esteve J; Ferrara F; Bolufer P; Bernasconi C; Gonzalez M; Rodeghiero F; Colomer D; Petti MC; Ribera JM; Mandelli F
    Blood; 2000 Aug; 96(4):1247-53. PubMed ID: 10942364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia.
    Azevedo MC; Velloso ED; Buccheri V; Chamone DA; Dorlhiac-Llacer PE
    Braz J Med Biol Res; 2015 Feb; 48(2):178-85. PubMed ID: 25517921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.
    Lengfelder E; Hanfstein B; Haferlach C; Braess J; Krug U; Spiekermann K; Haferlach T; Kreuzer KA; Serve H; Horst HA; Schnittger S; Aul C; Schultheis B; Erben P; Schneider S; Müller-Tidow C; Wörmann B; Berdel WE; Sauerland C; Heinecke A; Hehlmann R; Hofmann WK; Hiddemann W; Büchner T;
    Ann Hematol; 2013 Jan; 92(1):41-52. PubMed ID: 23090499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of Real-world Data on Postremission Therapy for Acute Myeloid Leukemia With Intermediate Risk Cytogenetics in First Complete Remission.
    Vydra J; Šálek C; Schwarz J; Žák P; Novák J; Petečuková V; Pecherková P; Mayer J; Cetkovský P; Ráčil Z
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):106-113. PubMed ID: 29289481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
    Wang L; Hu J; Sun Y; Huang H; Chen J; Li J; Ma J; Li J; Liang Y; Wang J; Li Y; Yu K; Hu J; Jin J; Wang C; Wu D; Xiao Y; Huang X
    Medicine (Baltimore); 2016 Jan; 95(4):e2560. PubMed ID: 26825897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study.
    Schaich M; Röllig C; Soucek S; Kramer M; Thiede C; Mohr B; Oelschlaegel U; Schmitz N; Stuhlmann R; Wandt H; Schäfer-Eckart K; Aulitzky W; Kaufmann M; Bodenstein H; Tischler J; Ho A; Krämer A; Bornhäuser M; Schetelig J; Ehninger G
    J Clin Oncol; 2011 Jul; 29(19):2696-702. PubMed ID: 21606413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
    Kohrt HE; Patel S; Ho M; Owen T; Pollyea DA; Majeti R; Gotlib J; Coutre S; Liedtke M; Berube C; Alizadeh AA; Medeiros BC
    Am J Hematol; 2010 Nov; 85(11):877-81. PubMed ID: 20872554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Ochs MA; Perissinotti AJ; Marini BL; Burke PW; Bixby DL; Pettit KM; Benitez LL
    Leuk Res; 2021 Mar; 102():106517. PubMed ID: 33561633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is cytarabine required in the treatment of acute promyelocytic leukemia?
    Adès L; Fenaux P
    Curr Hematol Malig Rep; 2006 Jun; 1(2):122-5. PubMed ID: 20425342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of standard-dose cytarabine in children with acute promyelocytic leukemia: a single-center experience.
    Zhang L; Zhu X; Chen X; Chen Y; Zou Y
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):e46-50. PubMed ID: 21127433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
    BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.
    Hanoun M; Ruhnke L; Kramer M; Hanoun C; Schäfer-Eckart K; Steffen B; Sauer T; Krause SW; Schliemann C; Mikesch JH; Kaufmann M; Hänel M; Jost E; Brümmendorf TH; Fransecky L; Kraus S; Einsele H; Niemann D; Neubauer A; Kullmer J; Seggewiss-Bernhard R; Görner M; Held G; Kaiser U; Scholl S; Hochhaus A; Reinhardt HC; Platzbecker U; Baldus CD; Müller-Tidow C; Bornhäuser M; Serve H; Röllig C;
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):4611-4621. PubMed ID: 36167894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study.
    Miyawaki S; Ohtake S; Fujisawa S; Kiyoi H; Shinagawa K; Usui N; Sakura T; Miyamura K; Nakaseko C; Miyazaki Y; Fujieda A; Nagai T; Yamane T; Taniwaki M; Takahashi M; Yagasaki F; Kimura Y; Asou N; Sakamaki H; Handa H; Honda S; Ohnishi K; Naoe T; Ohno R
    Blood; 2011 Feb; 117(8):2366-72. PubMed ID: 21190996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.